IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

PHILADELPHIA — Six-month data from the CLASP study showed a transcatheter mitral valve repair system for patients with functional mitral regurgitation conferred acceptable safety and statistically ...

Hausleiter J. First commercial multicenter experience with the PASCAL transcatheter valve repair system for tricuspid regurgitation. Presented at: TVT 2021. July 21. 2021. Miami, FL. MIAMI, FL—The ...

Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported. Several valve repair and replacement technologies, ...

Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “A minimally invasive, transcatheter leaflet strategy ...

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...